Summary
• Replimune GroupREPL-- (REPL) soars 94% intraday, hitting a new 52-week high of $12.50
• The biotech firm triggered a massive rally following a positive FDA panel vote and clinical trial updates
• Trading volume exploded to 7.45 million shares, with a turnover rate of 9.60% signaling intense institutional interest
• Options activity is frenzied, with the $11 and $12 calls dominating volume as traders bet on further upside
Replimune Group has shattered its recent consolidation pattern in a spectacular display of momentum. Driven by a pivotal FDA panel vote and encouraging clinical data, the stock has reclaimed its 52-week highs, catching the market off guard and igniting a wave of speculative buying across the biotech sector.
FDA Panel Vote Sparks Biotech Frenzy
The catalyst for this explosive 9.95% intraday surge is a direct response to regulatory breakthroughs. ReplimuneREPL-- Group received a favorable vote from an FDA advisory panel, a critical milestone for its oncolytic immunotherapy pipeline. This regulatory validation, combined with strong biopharma buying volume and positive clinical trial data updates, has fundamentally shifted investor sentiment. The market is rapidly repricing the company's potential, moving from a 'Hold' consensus to a momentum-driven breakout as traders rush to capture the upside of this therapeutic advancement.
Biotech Sector Rally Led by Moderna Momentum
While Replimune’s move is idiosyncratic to its regulatory news, it is amplifying broader sector strength. The biotechnology sector is showing resilience, led by Moderna (MRNA), which is up 2.17% intraday. This sector-wide momentum provides a supportive tailwind for REPLREPL--, allowing its regulatory catalyst to resonate with greater force. Investors are rotating into high-beta biotech names, and Replimune is currently the standout performer, outpacing sector leaders with its double-digit gain.
Leveraged Biotech ETFs and High-Gamma Options Play
The technical landscape for Replimune has shifted dramatically from a long-term ranging pattern to a short-term bullish breakout. Key technical indicators confirm the strength of this move:
• 30-Day Moving Average: $10.19 (Price is well above, confirming short-term bullish trend)
• 200-Day Moving Average: $7.83 (Price is significantly above, indicating strong long-term support)
• RSI: 54.72 (Neutral, suggesting room for further upside before overbought conditions)
• MACD Histogram: -0.336 (Negative but narrowing, hinting at momentum shift)
Traders should monitor the LABU (Direxion Daily S&P Biotech Bull 3X ETF), which tracks the broader biotech sentiment. With the stock breaking above the 30-day resistance zone of $11.13–$11.25, the path of least resistance is higher. For options traders, the implied volatility is elevated, reflecting the uncertainty and excitement of the event. We identify two high-potential contracts from the August 7 expiration chain that balance leverage, liquidity, and gamma exposure.
• Contract: REPL20260807C12REPL20260807C12 (Call), Strike: $12, Expiration: 2026-08-07
- IV Ratio: 321.03% (Extremely high implied volatility, indicating expensive premiums but high sensitivity)
- Leverage Ratio: 6.29% (High leverage, amplifying percentage moves in the underlying stock)
- Delta: 0.598 (At-the-money sensitivity, balanced risk/reward)
- Theta: -0.229 (High time decay, requiring quick price movement to profit)
- Gamma: 0.083 (High gamma, meaning delta will accelerate rapidly as price rises)
- Turnover: $199,592 (High liquidity, ensuring easy entry and exit)
- Description: This contract offers a balanced delta for aggressive bulls, with high gamma ensuring rapid profit accumulation if the stock holds above $12. The high turnover ensures you won't get stuck in a illiquid position.
• Contract: REPL20260807C13REPL20260807C13 (Call), Strike: $13, Expiration: 2026-08-07
- IV Ratio: 357.68% (Very high implied volatility, pricing in significant future movement)
- Leverage Ratio: 8.07% (Higher leverage than the $12 call, offering greater upside potential)
- Delta: 0.529 (Slightly out-of-the-money, but still highly sensitive to price changes)
- Theta: -0.249 (Very high time decay, demanding immediate upward momentum)
- Gamma: 0.077 (High gamma, providing strong convexity for quick rallies)
- Turnover: $54,662 (Moderate liquidity, sufficient for smaller positions)
- Description: This contract is a pure momentum play. If the stock breaks $12.50, the delta will expand rapidly, offering outsized returns. The high gamma and leverage make it ideal for a short-term breakout trade.
Options Payoff Calculation Primer: For this payoff estimation, we assume a 5% upside scenario from current price (12.3141) where for Call Option Payoff = max(0, ST - K) where ST is projected price and K is strike price and Put Option Payoff = max(0, K - ST) where ST is projected price and K is strike price. This projection helps evaluate option contracts' potential returns under a continued bullish move scenario.
Aggressive bulls may consider REPL20260807C12 into a bounce above $12.50.
Bullish Breakout Confirmed: Ride the Momentum
The 94% surge in Replimune Group is not a fluke but a fundamental repricing driven by regulatory success. The move is sustainable as long as the stock holds above the $11.13 support level. Investors should watch for a close above $12.50 to confirm the breakout. While the broader biotech sector, led by Moderna’s 2.17% gain, provides a supportive backdrop, Replimune’s unique catalyst sets it apart. Watch for $12.50 breakdown or further regulatory reaction.
